|Articles|July 15, 2002

BioPharm International

  • BioPharm International-07-01-2002
  • Volume 15
  • Issue 7

Virus Inactivation in the 1990's ? and into the 21st Century. Part 1: Skin, Bone, and Cells

Author(s)Gail Sofer

by Gail Sofer, BioReliance Viruses present dangers (and therefore challenges) to biopharmaceutical manufacturing processes. The virus inactivation method chosen depends on the virus and its surrounding medium. This survey article, organized by sample type, lists viral inactivation methods published during the past decade. Part 1 presents data for skin and bone and for cells that are not platelets or blood cells.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.